EUSA bags EU approval for kidney cancer drug
EUSA Pharma | August 29, 2017
The European Commission has licensed EUSA Pharma’s Fotivda for the management of adult patients with advanced kidney cancer across the European Union as well as Norway and Iceland. Fotivda (tivozanib) is indicated for the first line treatment of adults with advanced renal cell carcinoma (RCC) and for those who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy.